Related Experiment Video

Updated: Oct 2, 2025

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.2K

ND-16: A Novel Compound for Inhibiting the Growth of Cutaneous T Cell Lymphoma by Targeting JAK2

Man Zhu1, Yanhong Liu1, Panpan Lei1

  • 1School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, P.R. China.

Current Cancer Drug Targets
|February 28, 2022
PubMed
Abstract

Insights

ND-16, a novel nilotinib derivative, shows promise in treating cutaneous T cell lymphoma (CTCL) by targeting JAK2. This compound selectively inhibits CTCL H9 cells, inducing apoptosis and cell cycle arrest, suggesting potential therapeutic value.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Cutaneous T cell lymphoma (CTCL) is an aggressive extranodal non-Hodgkin lymphoma lacking curative treatments.
  • JAK2 amplification presents a potential therapeutic target in CTCL.
  • Nilotinib derivatives are being explored for their anticancer properties.

Purpose of the Study:

  • To evaluate the anticancer effects of ND-16, a novel nilotinib derivative, on CTCL cells.
  • To investigate the underlying mechanism of ND-16, focusing on JAK2 inhibition.
  • To assess the therapeutic potential of ND-16 in CTCL management.

Main Methods:

  • Surface plasmon resonance and molecular docking to confirm ND-16 binding to JAK2.
  • Inhibition of JAK2 downstream signaling pathways (STATs, PI3K/AKT/mTOR, MAPK).
  • Flow cytometry to analyze apoptosis and cell cycle arrest in ND-16 treated CTCL H9 cells.

Main Results:

  • ND-16 demonstrated selective inhibition of CTCL H9 cells.
  • ND-16 exhibited high binding affinity to JAK2.
  • ND-16 induced apoptosis and S-phase cell cycle arrest in H9 cells by modulating downstream signaling pathways and key proteins.

Conclusions:

  • ND-16 effectively targets JAK2 in CTCL cells.
  • ND-16 possesses significant anticancer effects on CTCL, including apoptosis induction and cell cycle arrest.
  • ND-16 represents a promising candidate for future CTCL therapy.
Keywords:
Cutaneous T-cell lymphomaJAK2ND-16apoptosisgrowthnovel compound

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.0K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K